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Reduction of proteinuria by angiotensin converting enzyme inhibition.
The effects of the angiotensin converting enzyme (ACE) inhibitor
lisinopril on blood pressure, proteinuria and renal hemodynamics were
evaluated in 13 patients with renal disease of different origin. A
comparison was made with the effects of conventional antihypertensive
therapy. Both drug regimens significantly lowered blood pressure,
while only after 12 weeks of treatment with lisinopril, blood pressure
was significantly lower than during conventional therapy. Lisinopril
reduced proteinuria (by 61 40%), whereas conventional therapy had
no significant effect on protein excretion. During the first eight weeks of
treatment with lisinopril, there was a comparable degree of blood
pressure reduction with both treatment regimens, whereas urinary
protein loss was significantly less during ACE inhibition. There was
only a nearly—significant positive correlation between the fall in pro-
teinuria during lisinopril and the concomitant decrease in mean arterial
pressure. Glomerular filtration rate decreased from 26.3 11.6 to 20.6
9.4 ml/min during treatment with lisinopril. This decrease was not
correlated with the fall in proteinuria. A significant positive correlation
existed between the fall in urinary protein excretion and both the
decrease in overall renal vascular resistance, and the fall in filtration
fraction. Although blood pressure lowering by itself could contribute to
the antiproteinuric effect of lisinopril, our results suggest that this effect
of ACE inhibition is also due to efferent (postglomerular) vasodilation.
We conclude that the ACE inhibitor lisinopril effectively reduces blood
pressure and proteinuria in renal disease, The latter effect is not only
the result of a lower blood pressure, but is probably also due to a fall in
intraglomerular capillary pressure.
Angiotensin converting enzyme (ACE) inhibitors are effec-
tive antihypertensive agents. Additionally, this group of drugs
has been found to induce renal vasodilation. Effective renal
plasma flow rises, whereas the glomerular filtration rate remains
constant, notwithstanding a fall in blood pressure [1—3]. The
concomitant fall in filtration fraction has been interpreted as a
fall in efferent (postglomerular) vascular tone. Data on the use
of ACE inhibitors in patients with renal function impairment
and proteinuria are scarce to date [4, 5]. Animal data suggest
that enalapril is able to protract the course of renal function
deterioration in the rat renal ablation model [6, 7], and in rats
with streptozotocin—induced diabetes mellitus [8, 9]. In these
studies ACE inhibitors prevented urinary protein loss [6—9].
Interestingly, the favorable effect on renal function and protein-
uria observed after treatment with enalapril was not present
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[10], or less pronounced [11], after reserpine, hydralazine, and
hydrochlorothiazide, or after verapamil [9]. Since only the ACE
inhibitor, and not other antihypertensives, caused a fall in
glomerular capillary pressure, notwithstanding a similar fall in
systemic blood pressure [10], it has been suggested that changes
in renal hemodynamics, induced by ACE inhibition, are respon-
sible for this benign effect on renal function [6—10]. Taguma et
al recently showed that captopril induced a fall in proteinuria in
patients with diabetic nephropathy [12]. We now extend these
observations to patients with renal function impairment and
proteinuria of various origin. In these patients blood pressure,
renal hemodynamics and proteinuria were studied during con-
ventional antihypertensive treatment, during a control period
without antihypertensive medication, and during a 12 week
course of ACE inhibition with lisinopril, a lysine analogue of
enalapril with a more prolonged duration of action.
Methods
Patients
Thirteen patients (7 male, 6 female) were enrolled in this
study. Mean age was 43.6 9.4 years. All gave their informed
consent and the study was approved by the Ethical Committee
of our hospital. All had renal function impairment, hypertension
and proteinuria. They used antihypertensive drug therapy,
generally a diuretic, beta—blocker, and vasodilator for at least
one year. Etiology of their renal disease and the conventional
antihypertensive drugs used are summarized in Table 1. In most
cases diagnosis was obtained by renal biopsy, except for the
patients with diabetic nephropathy (N = 3), polycystic kidney
disease (N = I) and chronic pyelonephritis (N = I). All patients
adhered to a dietary regimen of 3 to 5 g sodium chloride per day.
A protein intake of 30 to 40 glday had been advised to patients
with a creatinine clearance of less than 30 ml/min, and 40 to 60
g/day to patients with a creatinine clearance of 30 to 60 mI/mm,
from at least six months prior to the start of the study.
Concomitant medication consisted of iron supplementation,
multivitamins, phosphate binders, and vitamin D analogues in
most patients with a creatinine clearance less than 30 ml/min.
The sodium and protein content of the diet, as well as these
concomitant medications, were not changed during the entire
study period.
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Study protocol
All patients were followed in our out—patient hypertension
and nephrology unit. Blood pressure and biochemical parame-
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Table 1. Patient characteristics at entry during therapy with
conventional antihypertensive drugs
No. Sex Age Diagnosis Antihypertensivesa
I M 39 Chronic pyelonephritis furo 40/meto/I00/
pra 1.5
2 M 40 Membranoproliferative
GN**
meto 100/hydral 75
3 F 49 Polycystic kidney dis-
ease
HCT 50/meth 500
4 F 42 Diabetic nephropathy HCT 50
5 F 51 Diabetic nephropathy furo 40/don 450/
hydral 40
6 M 36 Membranoproliferative
ON
furo 40/meth 1500/
pra3
7 F 62 Diabetic nephropathy furo 80
8 F 45 Local focal glomeru-
losclerosis
don 450
9 M 49 Atherosclerosis/isch-
emia
meto 200
10 F 51 Atherosclerosis/isch-
emia
meto 200/pra 9/hy-
dral 200
II M 45 Wegener's granuloma-
tosis
HCT 50
12 M 26 Local focal glomeru-
loscierosis
meto 100
13 M 32 IgA glomerulopathy furo 40/meto 100
** ON = glomerulonephritis
furo, furosemide; meto, metoprolol; pra, prazosine; hydral, hydral-
azine; HCT, hydrochlorothiazide; meth, alphamethyldopa; don, cloni-
dine. Numbers refer to daily dose in mg.
ters were measured at least three times to obtain stable data
during conventional antihypertensive therapy. Thereafter, this
medication was withdrawn. They were without antihy-
pertensive therapy for two weeks before starting lisinopril,
except for the patients 6 and 10 who started therapy three and
five days after withdrawal of previous medication because of
clinically symptomatic, high blood pressures. Data obtained
before the start of lisinopril will be referred to as control period.
Lisinopril was gradually titrated from a starting dose of 2.5 or 5
mg once a day to a maximum of 40 mg o.i.d. The therapeutic
goal was a diastolic blood pressure of less than 95 mm Hg. If
blood pressure remained elevated notwithstanding this maxi-
mum dose of 40 mg lisinopril, a diuretic could be added
(furosemide 20 or 40 mg b.i.d.). Lisinopril was administered at
10a.m., separated by at least two hours from other medications
used. At days of out—patient visits, lisinopril was taken only
after blood pressure recordings and blood sampling had been
carried out. Blood was drawn for serum electrolytes, creatinine
and urea. At the control period (the day before lisinopril was
started), and at weeks 4, 8, and 12 during lisinopril treatment,
blood was also drawn for determination of ACE activity. The
day before every out—patient visit 24-hour urine was collected
for measurement of 24-hour protein excretion and creatinine
clearance. Additionally, the day before the first lisinopril dose
and after three months of treatment with the converting enzyme
inhibitor, glomerular filtration rate (GFR) and effective renal
plasma flow (ERPF) were measured with the patients in supine
position. After three hours of supine test, blood was drawn for
measurement of plasma renin activity (PRA) and plasma aldos-
terone concentration (PAC).
Table 2. Blood pressure, creatinine clearance and 24-hour protein
excretion in the patients at entry during conventional
antihypertensive treatment
No.
Blood
pressure
mm Hg
Creatinine
clearance
mi/mm
Protein
excretion
g/24 hr
1 134/92 22 2.4
2 146/100 56 0.5
3 156/100 38 0.9
4 162/90 35 12.4
5 232/104 25 7.8
6 126/90 19 4.4
7 186/92 22 3.5
8 162/90 55 0.4
9 150/94 48 3.9
10 170/110 13 1.5
11 170/98 10 2.2
12 148/92 15 6.3
13 134/98 IS 2.9
Data are the mean of three measurements.
Methods
Blood pressure was measured with a standard mercury
sphygmomanometer. Measurements were performed in triplo
after 10 minutes of supine rest. The mean of three readings,
differing not more than 10 mm Hg, was recorded. Mean arterial
pressure (MAP) was calculated as the diastolic blood pressure
plus one third of the difference between systolic and diastolic
pressure. Serum and urinary electrolytes, creatinine, and urea
were measured by a standard auto—analyzer technique. Urinary
protein was determined by biuret method in aliquots of 24-hour
urine collections. Serum angiotensin converting enzyme was
determined using a HPLC-assisted assay [13]. PRA and PAC
were measured by radioimmunoassay [14, 15]. GFR and ERPF
were measured simultaneously by constant infusion of 1251
iothalamate and '311-hippuran, respectively [16]. Both parame-
ters were corrected for standard body surface area (1.73 m2).
Filtration fraction (FF) is given as the quotient of GFR and
ERPF. Renal vascular resistance (RVR) is calculated as the
quotient of MAP and ERPF. Statistical analysis was performed
using Wilcoxon's test for paired data, since the parameters
involved (especially those on proteinuria) appeared to be non-
normally distributed. Data are given as mean SD, unless
otherwise indicated.
Results
Data on blood pressure, creatinine clearance, and 24-hour
protein excretion during conventional antihypertensive therapy
are given in Table 2. Creatinine clearance varied from 10 to 56
ml/min and 24-hour protein excretion ranged from 0.4 to 12.4
g!24 hr. Although a nephrotic range proteinuria (>5 g/24 hr) was
present in three patients, only one had a serum albumin content
of less than 30 g/liter.
After withdrawal of the antihypertensive drugs, systolic
blood pressure increased from 160 27 to 176 32 mm Hg (P
<0.01) and diastolic blood pressure rose from 96 6 to 110
10 mm Hg (P < 0.01). Proteinuria was 3.8 3.4 g/24 hr on
conventional therapy and 4.2 3.2 g/24 hr without antihyper-
tensive drugs. Although daily protein excretion during conven-
tional therapy was lower compared to control values in 10
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Fig. 1. Urinary protein excretion per 24 hours in the 13 patients during
conventional therapy (cony. ther.), the control period (control), and
after 4, 8, and 12 weeks of treatment with lisinopril. Open circles refer
to the patients who also received furosemide on week 12. The different
patients are identified by their number.
out of 13 patients (Fig. 1), the difference appeared to be not
statistically significant.
The average dose of lisinopril was 8.9 4.2 mg per day at
week 4, 20.8 14.7 mg per day at week 8, and 22.6 15.9 mg
per day at week 12. From week 8 through 12 the patients 4, 5,
and 7 also needed a diuretic (furosemide 20 or 40 mg b.i.d.) to
be added to the lisinopril treatment, because the goal diastolic
blood pressure was not met. Systolic blood pressure fell from
176 32 to 150 32 (P < 0.01), 147 30 (P <0.01), and 143
35 (P < 0.01) mm Hg at the 4th, 8th, and 12th week of
lisinopril, respectively. Diastolic blood pressure decreased
from 110 10to99 10(P< 0.01), 94 10(P <0.01), and88
5 mm Hg (P < 0.01), at week 4, 8, and 12 of lisinopril,
respectively. Both systolic and diastolic pressure were not
significantly different at week 4 and 8 of lisinopril treatment
compared to conventional therapy. However, at week 12 of
lisinopril treatment systolic (P < 0.05) and diastolic (P < 0.01)
blood pressure were lower compared to conventional treat-
ment. In the patients 4, 5, and 7, who also received a diuretic
from week 8 through 12, blood pressure was 174/104, 170/100,
and 214/96mm Hg at week 8, and 136/84, 216/96, and 222/94mm
Hg at week 12, respectively.
Already four weeks after the start of lisinopril, ACE activity
had decreased by 80 to 90 percent from 30.5 9.5 to 4.6 3.5
U/liter (P < 0.01), and remained stable at this low level during
the further course of lisinopril treatment. PRA had increased
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Fig. 2. Mean and SEM of proteinuria (A) and mean arterial pressure
(MAP, B) during conventional antihypertensive drugs (con. ther.), after
withdrawal of these drugs (control), and during lisinopril. The signifi-
cance of the difference compared to control is given at the top, and the
significance of the difference compared to the value during conventional
therapy is given at the bottom. * = P < 0.05 and ** = P < 0.01.
significantly from 1.35 1.23 to 20.1 19.7 nmol Al/liter/hr (P
<0.01) and PAC had fallen from 1.30 0.67 to 0.71 0.53
nmol/liter (P < 0.01) during lisinopril.
The changes in urinary protein excretion in the individual
patients during lisinopril treatment are shown in Figure 1.
Except for the patients 4, 7, and 13, there was a considerable
decrease in proteinuria. The changes in mean daily protein
excretion are given in Figure 2A. Proteinuria decreased signif-
icantly during lisinopril treatment from 4.2 3.2 to 2.9 2.9
g/24 hr (P < 0.01), 2.4 3.6 g/24 hr (P < 0.01), and 2.3 3.4
g/24 hr (P < 0.01) after 4, 8, and 12 weeks, respectively, thus
resulting in a total fall of 61 40% compared to control.
Comparing the daily protein excretion during conventional
therapy with the values of week 4, 8, and 12 of lisinopril
treatment, the differences appear to be statistically significant at
all periods (P <0.05, P < 0.01 and P < 0.01, respectively).
Figure 2B depicts the mean values of mean arterial pressure
(MAP) in the 13 patients at different study periods. Conven-
tional antihypertensive therapy, as well as lisinopril, lowered
blood pressure significantly. Although lisinopril in this particu-
lar study design appeared to be more effective at week 12 of
treatment compared to conventional treatment (P < 0.01), the
blood pressure effect of both regimens was not significantly
different at weeks 4 and 8 of lisinopril therapy. Thus, with a
comparable degree of blood pressure reduction on both
antihypertensive regimens during these periods, proteinuria
was significantly lower during ACE inhibition. There was a
positive correlation between the individual percentage of de-
crease in proteinuria after 12 weeks of lisinopril therapy and the
percentage of fall in MAP. This correlation however, was just
not statistically significant (r = 0.52, 0.05 < P < 0,10).
Serum creatinine, serum urea and creatinine clearance were
not significantly different on conventional therapy compared to
control (Table 3). During treatment with lisinopril a gradual but
not statistically significant rise in serum creatinine was ob-
served. Serum urea increased (P < 0.01) and creatinine clear-
ance decreased (P < 0.05) during therapy with this ACE
inhibitor. More accurate renal function studies were performed
in 11 patients during the control period, and after 12 weeks of
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Table 3. Biochemical parameters during previous antihypertensive medication, the control period, and during treatment with lisinopril
.Conventional
therapy Control
Lisinopril
Week 4 Week 8 Week 12
Serum sodium mmol/liter 140.7 2.4 139 3.7 139 3.5 139 2.7 138 2.3
Serum potassium mmol/liter 4.9 0.8 4.7 0.6 53 0.5" 5.4 0.6" 5.1 0.5"
Serum uric acid mmollliter 0.45 0.12 0.45 0.13 0.42 0.12 0.42 0.12 0.45 0.14
Serum creatinine ,jinol/liter 339 147 377 226 395 248 409 249 422 272
Creatinine clearance mI/mm 28.7 16.1 28.2 17.2 28.0 15.5 26.6 15.7 24.5 12.8a
Serum urea mmol/liter 17.1 6.5 15.1 6.5 17.3 6.4" 19.1 8.2" 21.9 144b
Urinary urea m,nol/24 hr 271 88 248 94 253 84 248 90 263 93
a p = <0.05
b p = <0.01
e ® e ®
GFR
Fig. 3. Changes in effective renal plasma flow (ERPF, by hippuran
clearance) and glomerular filtration rate (GFR, by iothalamate clear-
ance) in mI/mm/i .73 m2, and in filtration fraction (FF), during therapy
with lisinopril. Individual data of 11 patients (identified by their number)
are given at the control period (—) and after 12 weeks of treatment with
lisinopril (+). Open circles represent the values of the patients who
additionally received furosemide.
lisinopril treatment (Fig. 3). Lisinopril did not induce a signifi-
cant change in ERPF, which was 120 56 mI/mm during
control, and ill 52 ml/min after 12 weeks of lisinopril
treatment (NS). In contrast however, GFR fell in all subjects,
with a mean decrease of 21 10% (from 26.3 11.6 to 20.6
9.4 mI/mm, P < 0.01). Consequently, also a fall in FF was
observed (from 0.24 0.07 to 0.19 0.04, a decrease of 16.5
10.3%, P < 0.01), At the time of the second renal function
measurements, the patients 4, 5, and 7 also received diuretic
treatment. Interestingly, these three patients, in whom blood
pressure had not decreased significantly with lisinopril only,
had the lowest initial filtration fraction. These three subjects,
who all had diabetic nephropathy, responded with a fall in
ERPF. Two out of these three patients showed no fall in
proteinuria, not even after addition of furosemide. In the overall
group of patients, there was no correlation between the indi-
vidual percentual fall in GFR and the percentual fall in urinary
protein excretion (r =
—0.22, NS). The patients with the highest
FF during the control period showed the most pronounced fall
in FF during lisinopril (r = 0.82, P < 0.01), as well as the most
pronounced decrease in proteinuria (r = 0.72, P < 0.01). As a
consequence of the fall in MAP, with the stable ERPF, overall
renal vascular resistance (RVR) fell in most patients, although
RVR increased in the three patients using furosemide. We
found a significant positive correlation between the fall in
protein excretion and the fall in total RVR (Fig. 4A). A similar
positive correlation was observed between the fall in protein-
uria and the fall in FF (Fig. 4B). Thus, in the patients with the
most exaggerated fall in total RVR, as well as in FF (an index of
postglomerular vascular resistance), protein excretion fell
most.
Biochemical parameters were not different between conven-
tional therapy and control (Table 3). Serum sodium did not
change during treatment with lisinopril, whereas serum potas-
sium increased significantly. In fact, in five out of the 13
patients a rise in serum potassium of more than 1.0 mmol/liter
occurred, and in eight patients serum potassium levels of more
than 5.8 mmol/liter were observed. With additional dietary
advice regarding potassium containing foods, acceptable potas-
sium levels could be obtained. Serum uric acid did not change.
According to 24-hour urinary sodium excretion, mean sodium
intake was approximately 2 g higher than the dietary prescrip-
tion, and according to urea excretion protein intake was ap-
proximately 10 g higher than advised. Sodium and urea excre-
tions during lisinopril treatment were comparable to the excre-
tions during conventional therapy (Table 3). Serum albumin had
not changed during lisinopril treatment (38.2 5.3 g/liter at
control and 38.2 5.0 g!liter at week 12 of lisinopril therapy).
Discussion
Lisinopril effectively lowered ACE activity with a concomi-
tant rise in plasma renin activity and a fall in plasma aldosterone
concentration. This resulted in a significant reduction of blood
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pressure. During conventional antihypertensive therapy, blood
pressure was also significantly lower compared to control. Only
after 12 weeks of treatment with lisinopril, blood pressure was
significantly more reduced than during conventional therapy.
At weeks 4 and 8 of lisinopril treatment, however, the degree of
blood pressure lowering was not significantly different from
conventional antihypertensive treatment.
In most patients, urinary protein excretion was lower during
conventional therapy compared to control. However, this dif-
ference was not statistically significant. In contrast, lisinopril
significantly lowered proteinuria, compared to control, as well
as compared to conventional therapy. There appeared to be
only a nearly—significant positive correlation between the fall in
urinary protein excretion and decrease in MAP during
lisinopril. Moreover, during the first eight weeks of treatment
with lisinopril, there was a comparable degree of blood pressure
lowering on both therapeutic regimens, whereas proteinuria
was significantly more reduced during ACE inhibition. Thus,
although blood pressure lowering by itself could partially ex-
plain the fall in proteinuria during lisinopril, we argue that our
observations are in consonant with a more specific antiprotein-
uric effect of ACE inhibitors. This is in agreement with the data
of Taguma et al, who showed the proteinuria lowering effect of
captopril in patients with diabetic nephropathy without a con-
comitant fall in blood pressure [121.
It is likely to attribute these changes in protein leakage to an
interference of lisinopril with angiotensin-Il—mediated effects
on the kidney. Indeed, in animal experiments infusion of
angiotensin II caused a rise in urinary protein loss [17, 18]. This
angiotensin-Il—induced proteinuria has been attributed both to
changes in the permeability properties of the glomerular capil-
lary wall [17, 19], and alternatively to hemodynamic changes
with a concomitant rise in filtration fraction [18]. Also in man,
renin induced proteinuria has been described in cases of renal
artery stenosis [20—23]. Nephrectomy of the ischemic kidney
[21, 22], or treatment with captopril [231, has been found to
lower proteinuria in those conditions. Although we did not
systematically exclude the possibility of renal artery stenosis in
our patients, no clinical evidence of renovascular disease was
found.
Creatinine clearance gradually decreased during treatment
with lisinopril. Also glomerular filtration rate, measured as the
clearance of iothalamate, fell by 21% in our patients. The fall in
urinary protein excretion, however, was more pronounced
(61%). Thus fractional protein excretion also decreased. Since
no correlation existed between the fall in proteinuria and the fall
in GFR, we suggest that also other mechanisms are involved in
the antiproteinuric effect of lisinopril. ACE inhibitors are
known to induce renal vasodilation. In healthy volunteers and
in patients with essential hypertension and normal renal func-
tion, both captopril and enalapril induce a rise in ERPF [1—31.
We found no change in ERPF in our group of patients with renal
function impairment. This difference in response between pa-
tients with normal and with impaired renal function is probably
due to the renal disease itself. It may well be that these diseased
kidneys are unable to compensate for the fall in pressure with a
rise in flow. As a consequence, GFR and thus filtration fraction
fell. This is compatible with an efferent arteriolar (postglomer-
ular) vasodilation. Efferent vascular tone mainly is dependent
on angiotensin II [241. Thus, after ACE inhibition efferent
vasomotor tone will decrease. We observed a significant corre-
lation between the fall in urinary protein excretion and both the
fall in overall renal vascular resitance and the fall in filtration
fraction. This suggests that the fall in proteinuria is related to
the decrease in renal vascular resistance, particularly of
postglomerular arteriolar vessels. Such a postglomerular vaso-
dilation will result in a fall in intraglomerular capillary pressure.
Filtration of proteins consequently will decrease even more
than the filtration of the smaller molecular weight molecules like
creatinine or the GFR-marker iothalamate. This is in agreement
with the effect of enalapril in the rat renal ablation model [7] and
in streptozotocin—induced diabetes mellitus in the rat [8]. In the
latter study, the development of glomerulosclerosis and pro-
gressive albuminuria was prevented by normalizing glomerular
capillary pressure, as a consequence of the reduction of sys-
temic blood pressure as well as of postglomerular arteriolar
resistance.
It should be noted that the patients with the lowest filtration
fraction before lisinopril, especially the three patients with
diabetic nephropathy who also used furosemide at week 12, had
the smallest decrease in filtration fraction during ACE inhibi-
tion. This indicates an inability to dilate the efferent arteriole in
these patients. In fact, these three subjects showed a decrease
in ERPF, as well as a rise in renal vascular resistance. This
could have influenced the correlations plotted in Figure 4. The
different responses of these three patients may be explained by
the fact that they were less sensitive to ACE inhibition. Not
only blood pressure response was insufficient (which necessi-
tated the combination with a diuretic), but also renal vascular
resistance, filtration fraction, and proteinuria responded less
favorably compared to the other patients. The reason for this
insensitivity, especially where it seems to be related to the
underlying renal disease (diabetic nephropathy), remains un-
clear. On this point, our results are not in agreement with the
favorable effects of ACE inhibition on proteinuria in diabetic
nephropathy, observed by Taguma et a! [12].
Restriction of dietary protein intake can also lower protein-
uria [25]. In our patient group, however, the diet was not
changed with respect to protein intake from at least six months
before the study till the end. Moreover, urinary urea excretion,
which can be used as an estimate of protein intake, was
approximately stable during the entire observation period.
Therefore, we believe this did not significantly influence our
results.
Treatment with ACE inhibitors in patients with renal function
impairment bear the risk of a rise in serum potassium concen-
tration. We indeed found a significantly—higher serum potas-
sium during lisinopril, which, however, could be adjusted
acceptably with further dietary potassium restriction. Changes
in other biochemical parameters (Table 3) were not of clinical
importance. Finally, serum albumin did not rise, notwithstand-
ing the fall in urinary protein loss. One should however realize
that in most patients no hypoproteinemia existed before ther-
apy.
We thus conclude that converting enzyme inhibition results
in a fall in urinary protein excretion in patients with renal
function impairment. This antiproteinuric effect is not only due
to the antihypertensive effect of the drug, since a comparble
degree of blood pressure lowering with conventional drugs was
not accompanied by a similar decrease in urinary protein loss.
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We argue that this antiproteinuric effect likely is the conse-
quence of renal vasodilation, particularly of the efferent
arteriole, resulting in a fall in intraglomerular capillary pressure.
Whether these changes in intraglomerular pressure will also
contribute to protract the course of progressive renal failure
cannot be evaluated from our study, and has yet to be estab-
lished.
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